Federal Register #337-TA-1508

USITC investigation notice seeks submissions on remedies and public-interest issues for protein-studying products

The U.S. International Trade Commission (USITC) issued a notice in an investigation concerning products used to study proteins; this is not a procurement opportunity. - Government agency: USITC. The Office of Unfair Import Investigations is also a party to the investigation. - Named parties: Complainants are Seer, Inc. and The Brigham and Women’s Hospital. Nanomics Biotechnology Co., Ltd. is the sole respondent and was found in default. - Products involved: The investigation concerns imported systems, devices, software, compositions, chemicals, and laboratory supplies for studying proteins. No products or services are being requested for purchase, and no quantities or part numbers are provided. - Patents at issue: U.S. Patent Nos. 11,435,360; 11,630,112; 12,050,222; 12,228,566; and 12,590,948. - Notable requirements: The Commission invites written submissions addressing potential remedies, public-interest impacts, and bonding. It determined not to review the initial determination finding Nanomics Biotechnology Co., Ltd. in default.

Description

The U.S. International Trade Commission determined not to review an initial determination finding Nanomics Biotechnology Co., Ltd., the sole respondent in Investigation No. 337-TA-1508, in default. The investigation concerns alleged infringement of specified U.S. patents through the importation and sale of systems, devices, software, compositions, chemicals, and laboratory supplies for studying proteins. The Commission requests written submissions addressing potential remedies, public-interest factors, and bonding. Initial submissions are due October 30, 2026, and reply submissions are due November 6, 2026.

View original listing